Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer
- 4 February 2010
- journal article
- research article
- Published by Walter de Gruyter GmbH in cclm
- Vol. 48 (4), 505-512
- https://doi.org/10.1515/cclm.2010.095
Abstract
Background: Recent advanced techniques in glycobiology have produced a number of tumor marker candidates. As a result from the glycomic approach, we found that fucosylated haptoglobin in sera was a possible tumor marker for pancreatic cancer (PC). Although Aleuria aurantia lectin (AAL) blotting can detect fucosylated haptoglobin, it is difficult to quantify fucosylated haptoglobin precisely. To overcome this problem, we developed a fucosylated haptoglobin detection kit as a sandwich enzyme-linked immune sorbent assay (ELISA) using AAL and the Fab portion of anti-haptoglobin antibody. In the present study, we investigated the clinical application of this lectin-antibody ELISA kit to measure fucosylated haptoglobin in PC. Methods: We measured fucosylated haptoglobin in patients with PC with a lectin-antibody ELISA kit. The fucosylated haptoglobin measured with this assay was compared with lectin blotting data, and the discrepancy was analyzed by immunoprecipitation methods. The concentration of fucosylated haptoglobin was investigated with respect to the clinical stage of PC. We also measured fucosylated haptoglobin, using 397 cases of several types of cancers including PC, benign diseases, and normal controls. Results: The sensitivity and specificity for the differential diagnosis of PC from normal controls was 50% and 91%, respectively. The results from lectin-antibody ELISA were significantly correlated with data from previous AAL blotting studies. Positive rates of fucosylated haptoglobin with this method in patients with PC were significantly higher in cases of stage IV compared with other clinical stages. Fucosylated haptoglobin was increased in several types of cancers, in which fucosylated haptoglobin was reported to increase. Conclusions: While certain cases showed a discrepancy in fucosylated haptoglobin concentrations between the lectin-antibody ELISA and conventional lectin blotting, this novel type of lectin-antibody ELISA might be useful for a tumor marker for PC. Clin Chem Lab Med 2010;48:505–12.Keywords
This publication has 18 references indexed in Scilit:
- A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBritish Journal of Cancer, 2009
- Novel Fucosylated Biomarkers for the Early Detection of Hepatocellular CarcinomaCancer Epidemiology, Biomarkers & Prevention, 2009
- Automated immunoassay system for AFP–L3% using on-chip electrokinetic reaction and separation by affinity electrophoresisAnalytical Biochemistry, 2009
- Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: Final results of a randomized multi-institutional trialSurgery Today, 2008
- Adjuvant treatments for resectable pancreatic cancerJournal of Hepato-Biliary-Pancreatic Surgery, 2008
- Glycoprotein Microarrays with Multi-Lectin Detection: Unique Lectin Binding Patterns as a Tool for Classifying Normal, Chronic Pancreatitis and Pancreatic Cancer SeraJournal of Proteome Research, 2007
- Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylationInternational Journal of Cancer, 2006
- Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humansProceedings of the National Academy of Sciences of the United States of America, 2005
- ANALYSIS OF GLYCOPROTEIN-ASSOCIATED OLIGOSACCHARIDESAnnual Review of Biochemistry, 1993
- α-fetoprotein: Reevaluation in hepatologyHepatology, 1990